Holen Sie sich die Stockscreener-App
21.55
1.02%
0.3775
Handel nachbörslich:
21.57
0.0225
+0.10%
Kailera Therapeutics Inc Aktie (KLRA) Neueste Nachrichten
Meet the new IPO trying to take on Eli Lilly and Novo Nordisk in obesity - MSN
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Kailera Therapeutics (KLRA) Insider Trading Activity 2026 $KLRA - MarketBeat
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
This weight-loss drug challenger could follow Eli Lilly's playbook: Analyst - MSN
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - AOL.com
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? - AOL.com
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
Kailera Therapeutics IPO: Competing with Eli Lilly and Novo Nordisk in GLP-1 Weight LossNews and Statistics - IndexBox
Is Kailera Therapeutics a Buy After Its Sizzling IPO? - The Motley Fool
Is Kailera Therapeutics a Buy After Its Sizzling IPO? - The Motley Fool
How AI is Transforming Health Literacy and Engagement - William Blair
RTW Bio NAV Rises 7.0% In April As Biotech IPO And M&A Activity Accelerates - DirectorsTalk Interviews
Evercore Initiates Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
TD Cowen Initiates Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57 - Moomoo
Kailera Therapeutics, Inc. (KLRA) Total Expenses (TTM) - Zacks Investment Research
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst - Yahoo Finance
Kailera Therapeutics, Inc. (KLRA) Profit Margin (Quarterly) - Zacks Investment Research
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions - ChartMill
Kailera Therapeutics, Inc. (KLRA) Dividend Yield (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Market Cap - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Revenue (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Book Value (Per Share) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Net Income (Quarterly) - Zacks Investment Research
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity - Investor's Business Daily
Kailera's record IPO headlines strong April for biopharma financings - BioWorld News
A Quick Look at Today's Ratings for Kailera Therapeutics(KLRA.US), With a Forecast Between $30 to $48 - Moomoo
Kailera Therapeutics (KLRA) Stock Forecast and Price Target 2026 $KLRA - MarketBeat
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace
JPMorgan Initiates Kailera Therapeutics at Overweight With $30 Price Target - marketscreener.com
Leerink Initiates Kailera Therapeutics at Outperform With $36 Price Target - marketscreener.com
Evercore ISI Kailera Therapeutics Initiates at Outperform - Moomoo
William Blair Initiates Kailera Therapeutics at Outperform - Moomoo
Investment bank Leerink Partners announces the initiation of research coverage on biopharmaceutical company Kailera Therapeutics. - Bitget
TD Cowen initiates Kailera stock with buy on weight loss drug potential - Investing.com Canada
Top Hyperliquid Strategies (PURR) Competitors 2026 - MarketBeat
William Blair initiates Kailera stock with Outperform rating By Investing.com - Investing.com Canada
JPMorgan initiates Kailera stock at Overweight on obesity pipeline By Investing.com - Investing.com Canada
Kailera Therapeutics, Inc. (KLRA) Revenue (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Dividend (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Free Cash Flow (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Total Long Term Debt (Quarterly) - Zacks Investment Research
Odyssey raises $304 million in upsized Nasdaq debut - The Pharma Letter
Kailera Therapeutics, Inc. (KLRA) Price To Free Cash Flow - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Gross Profit (TTM) - Zacks Investment Research
KLRA: Kailera Therapeutics, Inc.12 Month EPS - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Earnings Yield (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Return On Equity (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
KLRA : Kailera Therapeutics, Inc. Key Company Details - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Cash From Financing (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Debt Equity Ratio (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Cash From Operations (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Book Value - Zacks Investment Research
Biotech firm Odyssey hits nearly $900 million valuation as shares rise in Nasdaq debut - WNWN-FM
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):